Literature DB >> 15315167

Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines.

Lili Yu1, Zehua Wang.   

Abstract

To investigate the expression of Bcl-2 and Bcl-xl gene in sensitive (A2780) and drug-resistance (AD6) human ovarian cancer cell lines and explore the molecular mechanism of multidrug resistance, A2780 and AD6 were detected by using DNA gel electrophoresis, flow cytometry and RT-PCR. Our results showed that (1) "DNA ladder" was observed in A2780 and AD6 after cisplatin treatment; (2) after 3.0, 6.0, 9.9 microg/ml of cisplatin treatment, a significant difference was noted in the rate of apoptosis between in A2780 and AD6 (P<0.05); (3) Bcl-2 and Bcl-xl genes were overexpressed in AD6. After cisplatin treatment, the expression of Bcl-2 and Bcl-xl genes was down-regulated in A2780 and AD6. It is concluded that cisplatin could induce the apoptosis of ovarian cancer cells, and the over-expression of Bcl-2 and Bcl-xl genes may contribute to apoptotic inhibition and the development of multidrug-resistance of human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315167     DOI: 10.1007/bf02885416

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

Review 1.  [High-dose chemotherapy in advanced epithelial ovarian cancer].

Authors:  H Curé; J O Bay; R Plagne; P Chollet; J Dauplat
Journal:  Bull Cancer       Date:  2001-09       Impact factor: 1.276

Review 2.  Chemotherapy-induced apoptosis.

Authors:  P W Mesner; I I Budihardjo; S H Kaufmann
Journal:  Adv Pharmacol       Date:  1997

3.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

Authors:  Z N Oltvai; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

4.  Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells.

Authors:  G Zhang; C Tu; G Zhang; G Zhou; W Zheng
Journal:  Leuk Res       Date:  2000-05       Impact factor: 3.156

5.  Fas-activated apoptosis and apoptosis mediators in human trabecular meshwork cells.

Authors:  R Agarwal; M Talati; W Lambert; A F Clark; S E Wilson; N Agarwal; R J Wordinger
Journal:  Exp Eye Res       Date:  1999-05       Impact factor: 3.467

6.  Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia.

Authors:  J S Kühl; S Krajewski; G E Durán; J C Reed; B I Sikic
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method.

Authors:  A Quattrone; L Papucci; V Santini; N Schiavone; D Noferini; A Calastretti; E Copreni; S Morelli; P L Rossi Ferrini; A Nicolin
Journal:  Haematologica       Date:  1995 Nov-Dec       Impact factor: 9.941

8.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

Authors:  T Miyashita; J C Reed
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113

9.  Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas.

Authors:  R E Meyn; L C Stephens; N R Hunter; L Milas
Journal:  Int J Cancer       Date:  1995-03-03       Impact factor: 7.396

  9 in total
  1 in total

1.  Correlation Between Immunohistochemical Biomarkers Expression and Prognosis of Ovarian Carcinomas in Tunisian Patients.

Authors:  Lobna Ayadi; Salma Chaabouni; Abdelmajid Khabir; Habib Amouri; Saloua Makni; Mohamed Guermazi; Mounir Frikha; Tahya Sellami Boudawara
Journal:  World J Oncol       Date:  2010-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.